The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

The Central Intelligence Agency with a "low confidence" has changed its stance and concluded that it's likely the COVI-19 ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...